Live Breaking News & Updates on Jnj 2113

Stay updated with breaking news from Jnj 2113. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Robert Bissonnette, MD: Safety Profile, Future Research on New Oral IL-23 Inhibitor for Psoriasis

During this segment of his interview, Bissonnette discussed safety data on JNJ-2113 for patients with plaque psoriasis and later went into future research topics. ....

Robert Bissonnette , Innovaderm Research , Chief Executive Officer , Il 23 , Jnj 2113 ,

Robert Bissonnette, MD: Discussing the First Oral IL-23 Inhibitor for Psoriasis

In this interview, Bissonnette spoke on the significance of the recent topline data on JNJ-2113 for patients with plaque psoriasis. ....

Robert Bissonnette , Innovaderm Research , Chief Executive Officer , Jnj 2113 , Il 23 ,

Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Five rusfertide abstracts accepted for oral and poster presentations at the 65th ASH Annual Meeting and Exposition (ASH2023)Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first- and only-in-class oral . ....

United States , New York , Yelena Ginzburg , Naveen Pemmaraju , Corey Davis , Dineshv Patel , Ellenk Ritchie , Roopa Taranath , Andrewt Kuykendall , Md Moffitt Cancer Center , Exchange Commission , Janssen Biotech Inc , Md Anderson Cancer Center , Phd Protagonist Therapeutics Inc , Development Rd Expenses , World Congress , International Congress On Myeloproliferative Neoplasms , Protagonist Therapeutics Inc , Protagonist Therapeutics , Polycythemia Vera , Recent Corporate , Janssen Biotech , Real World Analysis , Thromboembolic Event Rates , Moffitt Cancer Center , Hematocrit Control ,